Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

COPD: Management Using Bronchodilators and Corticosteroids01:26

COPD: Management Using Bronchodilators and Corticosteroids

1.2K
Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
1.2K
Drugs Used in Lower Respiratory Disorders: Overview01:17

Drugs Used in Lower Respiratory Disorders: Overview

1.6K
Lower respiratory tract disorders present challenges that often require skilled and nuanced approaches for effective management. Common ailments, such as asthma and chronic obstructive pulmonary disease (COPD), have prompted the development of intricate treatment strategies involving bronchodilators and anti-inflammatory drugs, each tailored to ease breathing and revitalize the lungs.
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
1.6K
COPD: Pathogenesis and Clinical Features01:20

COPD: Pathogenesis and Clinical Features

2.1K
Chronic obstructive pulmonary disease (COPD) is a group of lung conditions that progressively worsen over time, including chronic bronchitis and emphysema. This cluster of diseases collectively leads to a gradual and irreversible decline in lung function over time.
The primary cause for the onset of COPD is cigarette smoking and exposure to air pollution. These hazardous factors initiate a chain reaction within the lungs, resulting in chronic inflammation, damage to the airways, and a...
2.1K
Chronic Obstructive Pulmonary Disease-V: Management01:29

Chronic Obstructive Pulmonary Disease-V: Management

3.3K
Managing Chronic Obstructive Pulmonary Disease (COPD) involves a multifaceted approach to reduce symptoms, prevent exacerbations, improve overall health status, and slow disease progression. Key strategies include lifestyle modifications, pharmacotherapy, supportive therapies, and, in some cases, surgery. Here is an overview of the primary COPD management strategies:
Smoking Cessation
3.3K
Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

1.1K
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
1.1K
Asthma: Pathogenesis and Management01:20

Asthma: Pathogenesis and Management

1.5K
Asthma is a chronic pulmonary condition involving inflammation of the airways, hyper-reactivity, and reversible obstruction of the airways. This condition can significantly impact a person's quality of life, making breathing difficult and leading to distressing symptoms.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
1.5K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Resource impact of bronchiectasis and associated exacerbations: based on a 5-year prospective observational cohort study (BronchUK).

BMJ open respiratory research·2026
Same author

The CFTR potentiator icenticaftor for treatment of bronchiectasis: an international phase 2, double-blind, randomized placebo-controlled trial.

American journal of respiratory and critical care medicine·2026
Same author

A pragmatic, multicentre, placebo-controlled, 3-arm, double-blinded, randomised controlled trial, incorporating an internal pilot, to determine the role of bronchodilators in preventing exacerbations of bronchiectasis.

Health technology assessment (Winchester, England)·2026
Same author

Molecular endotyping in people with bronchiectasis based on response to antibiotic treatment: iBEST study.

ERJ open research·2025
Same author

Hypertonic Saline or Carbocisteine in Bronchiectasis.

The New England journal of medicine·2025
Same author

Eco-friendly Nano-scale Bio-analytical Insights for Spectrofluorimetric Estimation of Fimasartan Using Integrated Approach of Enhanced Microwave-assisted Hantzsch Reaction and Multicolored Analytical Chemistry.

Journal of fluorescence·2025

Related Experiment Video

Updated: May 4, 2026

Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma
14:39

Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma

Published on: November 4, 2010

34.4K

Bronchiectasis: an update on current pharmacotherapy and future perspectives.

Manjit K Sidhu1, Pallavi Mandal, Adam T Hill

  • 1Department of Respiratory Medicine, Royal Infirmary of Edinburgh , 51 Little France Crescent, Old Dalkeith Road, Edinburgh, EH16 4SA , UK +0131 242 1921 ; +0131 242 1870 ; manjitsidhu@doctors.org.uk.

Expert Opinion on Pharmacotherapy
|January 14, 2014
PubMed
Summary

Bronchiectasis treatment focuses on managing airway inflammation and infection. Current guidelines lack strong evidence, highlighting the need for more randomized controlled trials to improve patient care for this chronic lung condition.

More Related Videos

Author Spotlight: Exploring Non-Pharmacological Therapies for Chronic Respiratory Diseases — Linking Intestinal Microbiome Insights to COPD Treatment
03:25

Author Spotlight: Exploring Non-Pharmacological Therapies for Chronic Respiratory Diseases — Linking Intestinal Microbiome Insights to COPD Treatment

Published on: December 27, 2024

1.8K
P. aeruginosa Infected 3D Co-Culture of Bronchial Epithelial Cells and Macrophages at Air-Liquid Interface for Preclinical Evaluation of Anti-Infectives
10:26

P. aeruginosa Infected 3D Co-Culture of Bronchial Epithelial Cells and Macrophages at Air-Liquid Interface for Preclinical Evaluation of Anti-Infectives

Published on: June 15, 2020

10.5K

Related Experiment Videos

Last Updated: May 4, 2026

Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma
14:39

Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma

Published on: November 4, 2010

34.4K
Author Spotlight: Exploring Non-Pharmacological Therapies for Chronic Respiratory Diseases — Linking Intestinal Microbiome Insights to COPD Treatment
03:25

Author Spotlight: Exploring Non-Pharmacological Therapies for Chronic Respiratory Diseases — Linking Intestinal Microbiome Insights to COPD Treatment

Published on: December 27, 2024

1.8K
P. aeruginosa Infected 3D Co-Culture of Bronchial Epithelial Cells and Macrophages at Air-Liquid Interface for Preclinical Evaluation of Anti-Infectives
10:26

P. aeruginosa Infected 3D Co-Culture of Bronchial Epithelial Cells and Macrophages at Air-Liquid Interface for Preclinical Evaluation of Anti-Infectives

Published on: June 15, 2020

10.5K

Area of Science:

  • Pulmonology
  • Respiratory Medicine

Background:

  • Bronchiectasis is a common lung condition often complicating other chronic diseases like COPD and asthma.
  • Advanced bronchiectasis involves a cycle of neutrophilic inflammation and chronic infection, leading to cough and recurrent infections.

Purpose of the Study:

  • To review current pharmacotherapy and future treatment perspectives for adult bronchiectasis.
  • Focus on therapies addressing airway dilatation and breaking the infection-inflammation cycle.

Main Methods:

  • Systematic review of Phase III and above trials for bronchiectasis treatments.
  • Inclusion of landmark Phase II studies.
  • Search focused on optimizing airway dilatation and managing infection/inflammation.

Main Results:

  • Current treatment strategies are largely based on expert opinion (Grade D evidence).
  • Pharmacotherapies include antibiotics, anti-inflammatories, and mucoactive agents, alongside chest physiotherapy.

Conclusions:

  • There is a significant need for high-quality randomized controlled trials to advance evidence-based practice in bronchiectasis management.
  • Improved evidence is crucial for refining treatment guidelines and patient outcomes.